ZVRA

Zevra Therapeutics Inc

10.28

Oct 30 • 3:59 PM ET -0.08 (-0.77%)

10.28

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: RARE MIRM PTCT HRMY TVTX AGIO BMRN ETON DNLI BBIO

| Held by: VTI IWM JSMD VXF XPH IBB DFAS IWN VTWO JSML

Scroll to Statements

Index	RUT
Market Cap	610.47M
Enterprise Value	390.40M
Income	56.00M
Sales	136.07M
Book/sh	3.67
Cash/sh	3.73
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	61
IPO	Apr 16, 2015

P/E	11.09
Forward P/E	10.98
PEG	7.47
P/S	4.49
P/B	2.80
P/C	2.76
P/FCF	18.71
EV/EBITDA	9.64
EV/Sales	2.87
Quick Ratio	5.12
Current Ratio	5.17
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	0.93
EPS next Y	0.94
EPS next Q	0.16
EPS this Y	-17.88%
EPS next Y	-15.57%
EPS next 5Y	1.47%
EPS past 3/5Y	- -
Sales past 3/5Y	118.82% 51.62%
EPS Y/Y TTM	1868.38%
Sales Y/Y TTM	119.40%
EPS Q/Q	-89.97%
Sales Q/Q	53.25%
Earnings	Nov 03 AMC
EPS/Sales Surpr.	27.27% 17.06%

Insider Own	1.46%
Insider Trans	-11.38%
Inst Own	79.11%
Inst Trans	3.85%
ROA	20.03%
ROE	33.44%
ROIC	25.62%
Gross Margin	94.46%
Oper. Margin	28.71%
Profit Margin	41.15%
SMA20	-1.49%
SMA50	-8.03%
SMA200	-4.34%
Trades

Shs Outstand	59.34M
Shs Float	58.51M
Short Float	10.64%
Short Ratio	6.74
Short Interest	6.23M
52W High	15.03 -31.63%
52W Low	8.01 28.34%
Volatility	4.72% 4.67%
ATR (14)	0.46
RSI (14)	45.70
Beta	1.01
Rel Volume	0.70
Avg Volume	923.57K
Volume	642,059

Perf Week	4.79%
Perf Month	0.98%
Perf Quarter	2.24%
Perf Half Y	2.09%
Perf YTD	14.73%
Perf Year	1.38%
Perf 3Y	137.41%
Perf 5Y	8.21%
Perf 10Y	-83.09%
Recom	1.00
Target Price	25.25
Prev Close	10.36
Price	10.28
Change %	-0.77%

Consensus

Strong Buy

Avg. Price Target

$25.25

Implied Upside

+145.6%

Analysts7incl. previous ratings

Rating Distribution7 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Mar 16, 2026	Initiated	BBTIG Research	Buy	$23	+123.7%
Jul 02, 2025	Initiated	HH.C. Wainwright	Buy	$26	+152.9%
Jan 08, 2025	Resumed	CCantor Fitzgerald	Overweight	$25	+143.2%
Oct 07, 2024	Initiated	GGuggenheim	Buy	$20	+94.6%
Sep 24, 2024	Reiterated	MMaxim Group	Buy	$18 → $25	+143.2%
Sep 24, 2024	Initiated	JJMP Securities	Mkt Outperform	$17	+65.4%
Apr 02, 2024	Reiterated	MMaxim Group	Buy	$12 → $18	+75.1%
Mar 12, 2024	Initiated	WWilliam Blair	Outperform
Mar 17, 2023	Initiated	MMaxim Group	Buy	$12	+16.7%

Oct-26-26 11:29PM	Zevra's US MyPlyfa Momentum Faces A Test As EU Setback Drags Shares Lower (Earnings Whispers) +5.51%
Oct-20-26 07:30AM	Zevra Therapeutics Announces Details for Q3 2026 Financial Results Call (GlobeNewswire)
Sep-02-26 07:30AM	Zevra Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-25-26 07:30AM	Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium (GlobeNewswire)
Aug-21-26 04:30PM	Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
01:08AM	Loading…
Aug-06-26 01:08AM	Zevra Therapeutics Inc (ZVRA) (Q2 2026) Earnings Call Highlights: Revenue Surges 53% as ... (GuruFocus.com) +12.82%
Aug-05-26 05:15PM	Zevra Therapeutics: Q2 Earnings Snapshot (Associated Press)
04:05PM	Zevra Reports Second Quarter 2026 Financial Results and Corporate Update (GlobeNewswire)
Aug-04-26 07:30AM	Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference (GlobeNewswire)
Aug-03-26 07:30AM	Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA (arimoclomol) in Niemann-Pick Disease Type C (NPC) (GlobeNewswire) +5.73%
Jul-24-26 02:43PM	ZVRA Stock Sinks 23% On EU Setback Analyst Says Risk Is A Headwind, But Not Insurmountable (Stocktwits) -23.92%
10:38AM	Zevra Therapeutics Receives EMA Negative Opinion on Arimoclomol Marketing Application (InvestorsHub)
10:38AM	Zevra Therapeutics Receives EMA Negative Opinion on Arimoclomol Marketing Application (NASDAQ:ZVRA) (InvestorsHub)
08:48AM	ZVRA Stock Plummets Pre-Market, Heads For Worst Day In Over 5 Years Whats Driving The Sell-Off? (Stocktwits)
07:30AM	Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union (GlobeNewswire)
07:30AM	Loading…
Jul-22-26 07:30AM	Zevra Therapeutics Announces Details for Q2 2026 Financial Results Call (GlobeNewswire)
Jun-23-26 07:30AM	Zevra Therapeutics Announces Publication of Positive MIPLYFFA Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC) (GlobeNewswire)
Jun-11-26 08:30AM	Zevra's Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition (GlobeNewswire)
Jun-09-26 12:50PM	ZVRA Stock Hits Its Highest Levels In Nearly 5 Years Whats Driving This Sharp Rally Today? (Stocktwits) +12.99%
Jun-08-26 02:19PM	ZVRA Stock Way Undervalued? Analyst Sees 117% Upside After Patent Extends Exclusivity Till 2041 For Sole Approved Drug (Stocktwits) +13.95%
12:25PM	Zevra Therapeutics extends MIPLYFFA exclusivity to 2041 (Proactive)
07:30AM	Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA (GlobeNewswire)
May-29-26 04:30PM	Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-12-26 07:30AM	Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference (GlobeNewswire)
May-06-26 04:52PM	Zevra Therapeutics: Q1 Earnings Snapshot (Associated Press) +6.03%
04:05PM	Zevra Reports First Quarter 2026 Financial Results and Corporate Update (GlobeNewswire)
Apr-22-26 07:30AM	Zevra Therapeutics Announces Details for Q1 2026 Financial Results Call (GlobeNewswire)
Mar-20-26 04:30PM	Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-16-26 07:30AM	Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million (GlobeNewswire)
Mar-11-26 09:04PM	Zevra Therapeutics Inc (ZVRA) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Driven by ... (GuruFocus.com) -5.88%
02:45PM	Loading…
Mar-10-26 02:45PM	Why Is Zevra Therapeutics Stock Trading Higher Today? (Benzinga) +21.27%
08:30AM	GeneDx to Launch Genetic Testing Program with Zevra Therapeutics to Support Patients with Suspected Niemann-Pick Disease Type C (Business Wire)
Mar-09-26 04:40PM	Zevra Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Zevra Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Mar-05-26 07:30AM	Zevra Therapeutics Appoints Justin Renz as Chief Financial Officer (GlobeNewswire)
Mar-04-26 07:45AM	Stevanato Group (STVN) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
Mar-02-26 07:30AM	Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call (GlobeNewswire)
Feb-26-26 09:45AM	Aclaris Therapeutics (ACRS) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
Feb-25-26 12:15PM	Ironwood Pharmaceuticals (IRWD) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Zevra Therapeutics to Present at the Citizens Life Sciences Conference (GlobeNewswire)
Feb-24-26 05:22AM	GuruFocus Value Investing Contest Update (GuruFocus.com)
Feb-19-26 10:38AM	Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses (Newsfile)
Feb-18-26 01:51PM	Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses (Business Wire)
Feb-04-26 07:30AM	Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium (GlobeNewswire)
Feb-02-26 07:30AM	Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026 (GlobeNewswire)
Jan-26-26 07:30AM	Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA at the 22nd Annual WORLDSymposium (GlobeNewswire)
Jan-08-26 07:30AM	Zevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference (GlobeNewswire)
Dec-29-25 07:30AM	Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA for the Treatment of Niemann-Pick Disease Type C (NPC) (GlobeNewswire)
Dec-12-25 04:30PM	Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-02-25 07:30AM	Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD (GlobeNewswire)
Nov-20-25 04:05PM	Zevra Therapeutics, Inc. Announces CFO Transition (GlobeNewswire) -6.51%
Nov-06-25 12:03AM	Zevra Therapeutics Inc (ZVRA) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com) -9.73%
Nov-05-25 05:50PM	Zevra Therapeutics (ZVRA) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:48PM	Zevra Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Zevra Reports Third Quarter 2025 Financial Results and Corporate Update (GlobeNewswire)
Nov-04-25 08:21AM	What To Expect From Zevra Therapeutics Inc (ZVRA) Q3 2025 Earnings (GuruFocus.com)
Oct-29-25 07:30AM	Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference (GlobeNewswire) -8.66%
Oct-27-25 07:30AM	Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call (GlobeNewswire)
Oct-16-25 08:55AM	Zevra Therapeutics (ZVRA) Surges 12.3%: Is This an Indication of Further Gains? (Zacks)
Oct-06-25 05:51PM	Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +9.23%
01:10PM	Zevra Therapeutics Stock Sees Healthy RS Rating Jump To 73 (Investor's Business Daily)
Sep-25-25 05:22AM	Zevra Therapeutics (ZVRA) Soars 10.4%: Is Further Upside Left in the Stock? (Zacks) +6.37%
Sep-18-25 07:30AM	Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA (arimoclomol) and OLPRUVA (sodium phenylbutyrate) (GlobeNewswire) +8.32%
Sep-17-25 02:27PM	Zevra Therapeutics (ZVRA) Announces Positive New Data Supporting Foundational Role of MIPLYFFA for the Treatment of Niemann-Pick Disease Type C (Insider Monkey)
Sep-04-25 07:30AM	Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM) (GlobeNewswire)
Aug-28-25 07:30AM	Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM) (GlobeNewswire)
Aug-26-25 07:30AM	Zevra Therapeutics to Participate at Upcoming Investor Conferences in September (GlobeNewswire)
Aug-15-25 04:25PM	Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates (Revised) (Zacks) +5.96%
Aug-13-25 04:09PM	Zevra Therapeutics Crashes, Reversing 89% Run. Why It Could Be An 'Overreaction.' (Investor's Business Daily) -19.81% -5.62%
07:30AM	XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements (GlobeNewswire)
03:11AM	Zevra Therapeutics Inc (ZVRA) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Aug-12-25 05:50PM	Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:47PM	Zevra Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Zevra Reports Second Quarter 2025 Financial Results and Corporate Update (GlobeNewswire)
Aug-11-25 09:27AM	Zevra Therapeutics Inc (ZVRA) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
09:10AM	3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates (Zacks)
Aug-08-25 08:50AM	What Makes Zevra Therapeutics (ZVRA) a Good Fit for 'Trend Investing' (Zacks)
Aug-06-25 07:30AM	Zevra Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference (GlobeNewswire)
Aug-05-25 10:00AM	Zevra Therapeutics (ZVRA) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Aug-04-25 07:30AM	Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call (GlobeNewswire)
Jul-31-25 09:55AM	Does Zevra Therapeutics (ZVRA) Have the Potential to Rally 117.11% as Wall Street Analysts Expect? (Zacks)
Jul-28-25 06:00AM	Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C (GlobeNewswire)
Jul-18-25 07:30AM	Zevra Therapeutics Announces MIPLYFFA and OLPRUVA Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG) (GlobeNewswire)
Jul-17-25 09:11AM	Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics (Zacks)
Jul-16-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Zevra Therapeutics (ZVRA) is a Great Choice (Zacks)
09:01AM	5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats (Zacks)
07:30AM	Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism (GlobeNewswire)
Jul-15-25 09:55AM	Wall Street Analysts Predict an 86.55% Upside in Zevra Therapeutics (ZVRA): Here's What You Should Know (Zacks)
08:50AM	Here's Why 'Trend' Investors Would Love Betting on Zevra Therapeutics (ZVRA) (Zacks)
Jul-11-25 07:30AM	Zevra Therapeutics Announces MIPLYFFA (arimoclomol) Featured in Presentations at the National Niemann Pick Disease Foundation Conference (GlobeNewswire)
Jul-03-25 08:19AM	Zevra Therapeutics (ZVRA) Moves 5.1% Higher: Will This Strength Last? (Zacks)
May-29-25 04:35PM	Zevra Announces Final Results of 2025 Annual Meeting of Stockholders (GlobeNewswire)
May-27-25 01:03PM	Citizens JMP Reiterates Buy Rating on Zevra Therapeutics (ZVRA), Keeps PT (Insider Monkey)
May-21-25 07:30AM	All Three Leading Proxy Advisory Firms - ISS, Glass Lewis, and Egan-Jones - Recommend Zevra Stockholders Vote FOR the Company's Director Nominees (GlobeNewswire)
May-14-25 10:53AM	Q1 2025 Zevra Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
03:15AM	Zevra Therapeutics Inc (ZVRA) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges (GuruFocus.com)
May-13-25 05:20PM	Zevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:20PM	Zevra Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Zevra Reports First Quarter 2025 Financial Results and Corporate Update (GlobeNewswire)
May-12-25 09:33AM	Zevra Therapeutics Inc (ZVRA) Q1 2025 Earnings Report Preview: What To Expect (GuruFocus.com)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McFarlane Neil F.	President and CEO	Oct 12 '26	Sale	11.25	20,000	224,948	417,225	Oct 13 04:24 PM
NEIL F MCFARLANE	Director	Oct 12 '26	Proposed Sale	11.39	20,000	227,800		Oct 13 08:22 AM
Thompson Rahsaan	Chief Legal & Compliance	Aug 14 '26	Sale	11.13	42,666	474,774	37,569	Aug 17 04:32 PM
RAHSAAN THOMPSON	Officer	Aug 14 '26	Proposed Sale	11.18	42,666	477,006		Aug 14 04:31 PM
Watton Corey Michael	Director	Aug 10 '26	Option Exercise	4.97	12,300	61,131	14,100	Aug 12 04:16 PM
Watton Corey Michael	Director	Aug 10 '26	Sale	11.25	12,300	138,377	1,800	Aug 12 04:16 PM
JOHN BODE	Director	Jul 08 '26	Proposed Sale	14.85	10,516	156,163		Jul 08 04:01 PM
Thompson Rahsaan	Chief Legal & Compliance	Jun 22 '26	Sale	12.68	34,557	438,304	80,235	Jun 23 04:16 PM
Thompson Rahsaan	Chief Legal & Compliance	May 11 '26	Sale	11.30	1,794	20,272	48,125	May 13 04:32 PM
Rahsaan Thompson	Officer	May 11 '26	Proposed Sale	11.13	36,351	404,587		May 11 04:34 PM
Bode John B	Director	Mar 24 '26	Option Exercise	4.93	78,400	386,512	123,400	Mar 26 08:27 AM
RAYMOND L CLIFTON	Officer	Mar 16 '26	Proposed Sale	9.87	345,428	3,409,374		Mar 16 04:45 PM
McFarlane Neil F.	President and CEO	Feb 09 '26	Sale	8.56	14,625	125,186	387,225	Feb 10 04:49 PM
Sangiovanni Timothy J.	SVP, Finance & Corp Controller	Feb 03 '26	Sale	9.18	3,000	27,548	29,590	Feb 04 04:27 PM
Schafer Joshua	CCO	Feb 03 '26	Sale	9.19	10,500	96,500	62,278	Feb 04 04:27 PM
Sangiovanni Timothy J.	SVP, Finance & Corp Controller	Jan 30 '26	Sale	8.82	1,750	15,442	20,924	Feb 02 05:19 PM
Thompson Rahsaan	Chief Legal & Compliance	Jan 30 '26	Sale	8.83	4,080	36,010	49,919	Feb 02 05:19 PM
Quartel Adrian W	Chief Medical Officer	Jan 30 '26	Sale	8.83	4,533	40,036	9,723	Feb 02 05:19 PM
Schafer Joshua	CCO	Jan 30 '26	Sale	8.83	3,375	29,800	37,444	Feb 02 05:19 PM
McFarlane Neil F.	President and CEO	Feb 02 '26	Sale	9.38	91,000	853,425	364,350	Feb 02 05:18 PM
NEIL F MCFARLANE	Director	Feb 02 '26	Proposed Sale	9.00	105,625	950,625		Feb 02 04:32 PM
TIMOTHY SANGIOVANNI	Officer	Jan 30 '26	Proposed Sale	8.86	4,750	42,085		Jan 30 04:21 PM
R LaDuane Clifton	Former CFO & Treasurer	Jan 30 '26	Proposed Sale	8.86	14,000	124,040		Jan 30 04:20 PM
RAHSAAN THOMPSON	Officer	Jan 30 '26	Proposed Sale	8.86	4,080	36,149		Jan 30 04:19 PM
JOSHUA SCHAFER	Officer	Jan 30 '26	Proposed Sale	8.86	13,875	122,932		Jan 30 04:19 PM
ADRIAN QUARTEL	Officer	Jan 30 '26	Proposed Sale	8.86	4,533	40,162		Jan 30 04:19 PM
Clifton R. LaDuane	Former CFO & Treasurer	Dec 31 '25	Option Exercise	0.00	140,667	0	192,028	Jan 07 04:18 PM

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

PresidentMr. Neil F. McFarlane

Chief Legal OfficerMr. Rahsaan W. Thompson J.D.

MBAMr. Justin A. Renz CPA

Vice President of Investor Relations & Corporate CommunicationsMs. Nichol L. Ochsner

Chief People OfficerMs. Alison Peters

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ZVRA

Zevra Therapeutics Inc

Upgrade your Finviz experience